Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: paliperidone palmitate

« Back to Dashboard

Paliperidone palmitate is the generic ingredient in one branded drug marketed by Janssen Pharms and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are twenty-seven drug master file entries for paliperidone palmitate. One supplier is listed for this compound.

Summary for Generic Name: paliperidone palmitate

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Drug Master File Entries: see list27
Suppliers: see list1

Pharmacology for Ingredient: paliperidone palmitate

Clinical Trials for: paliperidone palmitate

Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism
Status: Withdrawn Condition: Bipolar Disorder

A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia
Status: Completed Condition: Schizophrenia

A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate
Status: Completed Condition: Schizophrenia

A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia
Status: Completed Condition: Schizophrenia

The Effect of Paliperidone Palmitate in Schizophrenia
Status: Recruiting Condition: Schizophrenia

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia
Status: Recruiting Condition: Schizophrenia (Recent-onset)

A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia
Status: Completed Condition: Schizophrenia

A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia
Status: Completed Condition: Schizophrenia

A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia
Status: Completed Condition: Schizophrenia

Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)
Status: Completed Condition: Schizophrenia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264Jul 31, 2009RXNo<disabled><disabled>
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264Jul 31, 2009RXYes<disabled><disabled>
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264Jul 31, 2009RXYes6,555,544*PED<disabled>Y<disabled>
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264Jul 31, 2009RXNo6,555,544*PED<disabled>Y<disabled>
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264Jul 31, 2009RXYes5,254,556*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc